Public Health Agency of Canada
Symbol of the Government of Canada

Information on immunization programs was collected by the Canadian Nursing Coalition on Immunization (CNCI). PHAC and the CNCI have worked together since July 2004 to develop this tool containing the latest provincial/territorial program information.

Publicly funded Immunization Programs in Canada - Routine Schedule for Infants and Children (including special programs and catch-up programs)

Province/ Territory DTaP-IPV-Hib DTaP-IPV Td, Tdap
or
Td-IPV
HB MMR Var MMRV Men-C Men-C-A, C, Y, W-135 Pneu-C-7 Pneu-C-10 Pneu-C-13 Inf HPV Rot
NACI recom- mendation 2, 4, 6, 18 mths 4-6 yrs 14-16 yrs Infancy (3 doses) OR Pre-teen/teen (2-3 doses) 12 mths
AND 18 mths OR
4-6 yrs
12-18 mths
(1 dose)
12 mths AND 18 mths OR 4-6 yrs Infancy (1-4 doses)1 AND Pre-teen (1 dose) 1 Pre-teen (1 dose) 1 2, 4, 6, 12-15 mths 2, 4, 6, 12-15 mths 2, 4, 6, 12-15 mths 6-23 mths (1-2 doses) Females 9-13 yrs (3 doses at 0, 2, 6 mths)2 2, 4, 6 mths
BC 2, 4, 6 (DTaP- HB-IPV-Hib); 18 mths (DTaP-IPV-Hib) 4-6 yrs Tdap, Gr. 9 2, 4, 6 mths (DTaP- HB-IPV-Hib); Catch-up
Gr. 6 (HB)
12, 18 mths 12 mths, Catch-up 4-6 yrs, Gr. 6   2, 12 mths;
Gr. 6
      2, 4, (6 HR), 12 mths 6-23 mths Females Gr. 6, 9  
AB 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 Gr. 5 12 mths, 4-6 yrs 12 mths   2, 4, 12 mths Planned use in 2011: Gr. 9 (1 dose) 2, 4, 6, 18 mths     6-59 mths Females Gr. 5; Catch-up Gr. 9 in 2009-12  
SK 2, 4, 6, 18 mths 4-6 yrs Tdap,
Gr. 8, contacts of infants
Gr. 6 18 mths;
Catch up
Gr. 8, 12
12 mths; Catch-up
Gr. 6
October 2010: 12 mths 12 mths, 4-6 yrs; Catch up Gr. 6       2, 4, 6, 18 mths 6-59 mths Females Gr. 6  
MB 2, 4, 6, 18 mths 4-6 yrs Tdap, 14-16 yrs Gr. 4 12 mths, 4-6 yrs 12 mths; Catch-up
4-6 yrs,
Gr. 4
  12 mths; Catch-up Gr. 4       2, 4, 6, 18 mths 2010-11 ≥ 6 mths Females Gr. 6  
ON 2, 4, 6, 18 mths 4-6 yrs Tdap, 14-16 yrs Gr. 7 12, 18 mths 15 mths; Catch-up 4-6 yrs   12 mths; Catch up Gr. 7, 14-16 yrs Gr. 7   2, 4, 6, 15 mths   ≥ 6 mths Females Gr. 8  
QC 2, 4, 6, 18 mths 4-6 yrs Tdap, 14-16 yrs Gr. 4 18 mths Catch-up 4-6 yrs, Gr. 4 12 mths 12 mths; Catch-up < 18 yrs       2, 4, 12 mths  6-23 mths Females Gr. 4 (2 doses), 3rd year of high school (1 dose); Catch-up Females < 18 yrs  
NB 2, 4, 6, 18 mths 4 yrs Tdap, Gr. 9 0, 2, 6 mths 12, 18 mths, Catch-up Gr. 12 2007-13 12, 18 mths (if born in 2009 or later). One dose if born between 2000 and 2008 Planned use in 2011  12 mths Gr. 9     2, 4, 6, 12 mths; Catch-up if born between June 30th, 2008 and July 1st, 2009 (1 dose) 6 mths – 18 yrs Females Gr. 7  
NS 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 7, and 8 for 2010-11 only Gr. 7 12 mths, 4-6 yrs 12 mths; Catch-up 1-6 yrs   12 mths; Catch-up Gr. 7       2, 4, 6, 18 mths ≥ 6 mths Females Gr. 7, and 8 for 2010-11 only  
PE 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 2, 4, 15 mths 15, 18 mths 12 mths   12 mths Gr. 9 2, 4, 6, 18 mths       Females Gr. 6 2 mths (if born in October 2010 or later)  
NL 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 Gr. 4
(3 doses)
12, 18 mths 12 mths   12 mths Catch-up Gr. 4   2, 4, 6, 18 mths   6-23 mths Females Gr. 6  
NT 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 0, 1, 6 mths 12, 18 mths, Post secondary students attending schools outside NT 12 mths; Catch-up <5 yrs   2, 12 mths; Catch-up <5 yrs, Gr. 9 Post secondary students attending schools outside NT     2, 4, 6, 18 mths 6-23 mths Females Gr. 4; Catch-up Gr. 9-12 2009-14  
YT 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 2, 4, 12 mths; Catch-up ≤ 19 yrs 12, 18 mths 12 mths   2, 12 mths; Catch-up Gr. 9, post-secondary students not previously immunized   2, 4, 6, 18 mths     > 6mths Females Gr. 6; Catch-up Gr. 7, 8  
NU 2, 4, 6, 18 mths 4-6 yrs Tdap, Gr. 9 (14-16 yrs) 0, 1, 9 mths 12, 18 mths; Catch-up Gr. 12 15 mths   12 mths; Catch-up Gr. 9 (14-16 yrs)       2, 4, 6, 15 mths, Pneu-P-23 2-3 yrs  Universal ≥ 6 mths Females Gr. 6 (≥ 9 yrs)  
 

Legend:

DTaP: Diphtheria, Tetanus, Acellular Pertussis
HB: Hepatitis B
Hib: Haemophilus Influenzae Tybe b
HPV: Human Papillomavirus
Inf: Influenza
IPV: Inactivated Polio
Men-C: Meningococcal conjugate
MMR: Measles, Mumps, Rubella
MMRV: Measles, Mumps, Rubella, and Varicella
Pneu-C-7, Pneu-C-10, Pneu-C-13:
Pneumococcal conjugate 7, 10, and 13 valent
Pneu-P-23: Pneumococcal polysaccharide 23 valent
Rot: Rotavirus
Var: Varicella

Recommended use:

1. If meningococcal C conjugate vaccine is given to infants < 12 months of age, a booster dose should be given in the second year of life (from 12 to 23 months of age). The early adolescent dose may be given using either meningococcal C conjugate (Men-C) vaccine or quadrivalent conjugate meningococcal vaccine (Men-C-ACYW) depending on the burden of illness from serogroups A, Y and W135 and the age distribution of cases by serogroup in individual Provinces / territories. Updated Invasive Meningococcal Vaccine Conjugate Recommendations can be found at:
http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09pdf/acs-dcc-3.pdf PDF Version

2. The HPV vaccine is recommended for females between 9 and 13 years of age, as this is before the onset of sexual intercourse for most females in Canada, and the efficacy would be greatest. Females between the ages of 14 and 26 years would benefit from the HPV vaccine, even if they are already sexually active, as they may not yet have HPV infection and are very unlikely to have been infected with all four HPV types in the vaccine. Females between the ages of 14 and 26 years who have had previous Pap abnormalities, including cervical cancer, or have had genital warts or known HPV infection would still benefit from the HPV vaccine.